Trametinib, DMSO Solvate, >99%

• Solubility: DMSO.

View the SDS for this product

• This research compound is the DMSO solvate form of trametinib; please see the other form of this product, Cat. No. T-8123, Trametinib, Free Base, for further technical information about both of these research compounds.
• Trametinib dimethyl sulfoxide is the active ingredient in the drug product sold under the trade name Mekinist®.  This drug is currently approved in a least one country for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.  NOTE:  THE TRAMETINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT MEKINIST®, AND IS NOT FOR HUMAN USE.
• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
• Not available in some countries; not available to some institutions; not available for some uses.